A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT06937749 on ClinicalTrials.gov · last registry update 2025-11-20
Recruiting now, toward 165 participants. Its estimated completion date, 30 April 2026, has passed with no update to the record. Primary outcome, as filed: Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 165
- Started
- 2025-07-01
- Primary completion
- 2026-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology
Conditions studied
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.